NEW COMPOUNDS Russian patent published in 2012 - IPC C07D213/74 C07D213/75 C07D213/81 C07D213/82 C07D237/20 C07D239/42 C07D263/48 C07D277/42 C07D401/10 C07D401/12 C07D401/14 C07D405/12 C07D413/10 C07D413/12 A61K31/44 A61P3/00 

FIELD: medicine, pharmaceutics.

SUBSTANCE: invention refers to compounds of formula: wherein B is specified in a group consisting of pyridine, pyridazine, pyrimidine and oxazole which can be optionally substituted by halogen, C_1-7-alkyl or a C_1-7-alkoxy group; L1 is specified in a group consisting of -NH-, -C(O)NH- and -NHC(O)-, A means C₃-C₁₂-cycloalkyl, C₆-C₁₂-aryl, a 4-7-member monocyclic heterocyclic group consisting of 1-3 heteroatoms optionally specified in O N and S, or a bicyclic heterocyclyl specified in a group consisting of benzimidazolyl, benzoxazolyl, benzothiazolyl, wherein cycloalkyl, aryl, mono- or bicyclic heterocyclyl can be optionally substituted by one or more substitutes optionally specified in a group consisting of a cyano group, halogen, an oxo group, C_1-7-alkyl, C_1-7-halogenalkyl, a C_1-7-alkoxy group, C_1-7-halogenalkoxy group, an amino group, a di-C_1-7-alkylamino group, a C_1-7-alkylthio group and C_3-8-cycloalkyl, 1-2- means a bivalent residue specified in a group consisting of: - a bivalent alkyl group consisting of 1 to 4 carbon atoms, a bivalent alkenyl group consisting of 2 to 3 carbon atoms, - -C(O)-, - -C(O)-[R⁴]_c-R⁵- wherein c is equal to 0, and R⁵ is specified in a group consisting of a bivalent C₁-C₄-alkyl group optionally substituted by another C₁-₄-alkyl, a C₄-C₈-cycloalkyl group, a phenyl group and a 5- or 6-member heterocyclyl group consisting of N heteroatoms, - -C(O)-NH-, - -(CH₂)_1-3-C(O)-NH-(CH₂)_1-3-, - -C(O)-NH-R⁴- wherein R⁴ is specified in a group consisting of a bivalent C₁-C₇-alkyl group optionally substituted by another C_1-4-alkyl, a cyclohexyl group and a cyclopentyl group, and E is specified in a group consisting of: - COOH, - a ester group of carboxylic acid, or to its pharmaceutically acceptable salts. What is also described is a pharmaceutical composition exhibiting DGAT1 modulatory activity, on the basis of the presented compounds, and also a method of treating pathological conditions or disorders associated with DGAT1 activity.

EFFECT: there are prepared and described new compounds applicable for treating or preventing the pathological conditions or disorders associated with DGAT1 activity.

22 cl, 8 ex